Biorem Inc (TSE:BRM)
:BRM
Want to see TSE:BRM full AI Analyst Report?
BRM Stock Chart & Stats
C$2.65
-C$0.02(-0.63%)
At close: 4:00 PM EST
C$2.65
-C$0.02(-0.63%)
Day’s Range― - ―
52-Week RangeC$1.67 - C$3.33
Previous CloseN/A
Volume29.81K
Average Volume (3M)32.44K
Market Cap
C$52.22M
Enterprise ValueC$44.51M
Total Cash (Recent Filing)C$11.50M
Total Debt (Recent Filing)C$2.83M
Price to Earnings (P/E)9.0
Beta0.53
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,117,027
10 Day Avg. Volume30,537
30 Day Avg. Volume32,440
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)2.90
Price to Sales (P/S)1.02
P/FCF Ratio5.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.28
Revenue Forecast (FY)C$45.20M
Bulls Say, Bears Say
Bulls Say
Revenue & Margin ExpansionBiorem’s 2025 revenue growth (~22%) and margin expansion (net ~11% vs ~8%) reflect improved operating leverage and scalable project economics. Sustained higher margins bolster internal cash for aftermarket services and reinvestment, supporting durable profitability and ability to fund growth over coming quarters.
Improved Balance Sheet / Lower LeverageLeverage falling to ~0.19 in 2025 from materially higher levels improves financial flexibility and reduces interest burden. A healthier capital structure supports bidding on engineered projects, cushions working-capital swings, and lowers refinancing risk, enabling steadier execution over the medium term.
Strong Cash GenerationOperating cash flow of ~$7.6M and free cash flow ~$7.3M demonstrates strong cash conversion and high earnings quality in 2025. Reliable free cash provides durable funding for aftermarket service growth, modest capital needs, and reduces dependency on external financing for near-term project execution and strategic initiatives.
Bears Say
Historical Revenue & Earnings VolatilityBiorem’s multi-year trend includes notable volatility, including a 2023 revenue decline, indicating sensitivity to project cycles and end-market demand. This uneven growth undermines predictability for bookings, margins and cash flow, making operational planning and steady margin expansion harder to sustain over time.
Working-Capital / Project Timing RiskAs an engineered-project business, Biorem’s cash is sensitive to project scheduling and working-capital timing, causing swings in operating and free cash flow. These timing-driven gaps can create short-term liquidity stress, constrain investment capacity, and require external funding during weaker quarters or large project transitions.
ROE Sensitivity To Capital StructureReported high ROE partially stems from historically thin equity, which makes returns highly sensitive to balance-sheet shifts. If management increases leverage again to fund projects or cover timing gaps, ROE and reported profitability could swing sharply while financial risk and borrowing costs rise, weakening long-term stability.
Biorem Inc News
BRM FAQ
What was Biorem Inc’s price range in the past 12 months?
Biorem Inc lowest stock price was C$1.67 and its highest was C$3.33 in the past 12 months.
What is Biorem Inc’s market cap?
Biorem Inc’s market cap is C$52.22M.
When is Biorem Inc’s upcoming earnings report date?
Biorem Inc’s upcoming earnings report date is May 14, 2026 which is in 14 days.
How were Biorem Inc’s earnings last quarter?
Currently, no data Available
Is Biorem Inc overvalued?
According to Wall Street analysts Biorem Inc’s price is currently Overvalued.
Does Biorem Inc pay dividends?
Biorem Inc does not currently pay dividends.
What is Biorem Inc’s EPS estimate?
Biorem Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biorem Inc have?
Biorem Inc has 16,117,027 shares outstanding.
What happened to Biorem Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biorem Inc?
Currently, no hedge funds are holding shares in TSE:BRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biorem Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.30%
12-Months-Change
Fundamentals
Return on Equity
39.51%
Trailing 12-Months
Asset Growth
17.77%
Trailing 12-Months
Company Description
Biorem Inc
BioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company operates in Canada, the United States, China, and internationally. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.
Technical Analysis
Dundee Sustainable Technologies
―
Sharc International Systems Inc
―
Questor Technology
―
Thermal Energy International
―
Greenlane Renewables Inc
―
Options Prices
Currently, No data available
---